Coherus Biosciences ( (CHRS) ) has released its Q1 earnings. Here is a breakdown of the information Coherus Biosciences presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Coherus BioSciences, Inc. is a commercial-stage oncology company focused on developing innovative cancer treatments, with a portfolio that includes the FDA-approved PD-1 inhibitor LOQTORZI and a promising pipeline of immuno-oncology candidates.
In its first quarter of 2025, Coherus BioSciences reported significant strategic and financial developments, including the completion of its transformation into an innovative oncology company and the divestiture of its UDENYCA franchise. The company highlighted positive clinical data from its CHS-114 Phase 1b study and ongoing trials for its pipeline candidates.
Key financial metrics for the quarter included net revenue from continuing operations of $7.6 million, primarily driven by LOQTORZI sales, and a net loss from continuing operations of $47.4 million, showing an improvement from the previous year’s loss. The divestiture of UDENYCA brought in a substantial upfront payment, positioning the company for future growth in its oncology focus.
Coherus is actively advancing its oncology pipeline, with ongoing studies for CHS-114 and casdozokitug in various cancer indications. The company is also exploring partnerships to expand LOQTORZI’s label and enhance its market presence.
Looking ahead, Coherus BioSciences is poised to leverage its innovative oncology portfolio to drive growth and improve cancer treatment outcomes, with key data milestones anticipated in 2026.